Phosphorus MR spectroscopy in the treatment of human extremity sarcomas

NMR in Biomedicine

Volumn 11, Issue 7, 1998, Pages 341-353

  Sijens, P E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Human extremity tumors; Magnetic resonance spectroscopy; Phosphorus; Sarcoma

Indexed keywords

CARMUSTINE; PHOSPHORUS 31; TUMOR NECROSIS FACTOR;

DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIA; LIMB TUMOR; OSTEOSARCOMA; PHOSPHATE METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTION; PRIORITY JOURNAL; REVIEW; SARCOMA; SPECTRAL SENSITIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; EXTREMITIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PHOSPHORUS RADIOISOTOPES; RADIOTHERAPY; SARCOMA; SARCOMA, EXPERIMENTAL;

MURINAE;

EID: 0031790547     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1492(1998110)11:7<341::AID-NBM516>3.0.CO;2-U     Document Type: Review

References (73)

1. 31P-NMR studies of a human tumour in situ. Lancet i, 1435-1436 (1983).
2. Nidecker A. C., Müller S., Aue W. P., Seelig J., Fridrich R., Remagen W., Hartweg H. and Bentz U. F. Extremity bone tumors: evaluation by P-31 MR spectroscopy. Radiology 157, 167-174 (1985).
3. 31Phosphorspektroskopie bei osteogenem Sarkom; Möglichkeiten der Therapiekontrolle imm Vergleich mit bildsebenden Verfahren. Fortschr. Röontgenstr. 146, 144-148 (1987).
4. Ross B., Helsper J. T., Cox I. J., Young I. R., Kempf R., Makepeace A. and Pennock J. Osteosarcoma and other neoplasms of bone; magnetic resonance spectroscopy to monitor therapy. Arch. Surg. 122, 1464-1469 (1987).
5. Bryant D. J., Bydder G. M., Case H. A., Collins A. G., Cox I. J., Makepeace A. and Pennock J. M. Use of phosphorus-31 MR spectroscopy to monitor response to chemotherapy in nonHodgkin lymphoma. J. Comput. Assist. Tomogr. 12, 770-774 (1988).
6. Semmler W., Gademan G., Schlag P., Bachert-Baumann P., Zabel H. J., Lorenz W. J. and von Kaick G. Impact of hyperthermic regional perfusion therapy on cell metabolism of malignant melanoma monitored by P MR spectroscopy. Magn. Reson. Imag. 6, 335-340 (1988).
7. 31P MR spectroscopy. Radiology 166, 533-539 (1988).
8. Lenkinski R. E., Listerud J., Shinkwin M. A., Zladkin M. B., Kressel H. Y., Schmidt R. G. and Daly J. M. Magnetic resonance imaging and magnetic resonance spectroscopy of bone tumors and bone marrow disease. Invest. Radiol. 12, 1006-1010 (1989).
9. Redmond O. M., Stack J. P., Dervan P. A., Hurson B. J., Carney D. N. and Ennis J. T. Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making. Radiology 172, 811-815 (1989).
10. Negendank W. G., Crowley M. G., Ryan J. R., Keller N. A. and Evelhoch J. L. Bone and soft tissue lesions: diagnosis with combined H-1 MR imaging and P-31 MR spectroscopy. Radiology 173, 181-188 (1989).
11. 31P NMR spectra of extremity sarcomas: diversity of metabolic profiles and changes in response to chemotherapy. Magn. Reson. Med. 16, 19-34 (1990).
12. Dewhirst M. W., Sostman H. D., Leopold K., Charles H. C., Moore D., Burn R. A., Tucker J. A., Harrolson J. M. and Oleson J. Softtissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Radiology 174, 847-853 (1990).
13. Sostman H. D., Charles H C., Rockwell S., Leopold K., Beam C., Madwed D., Dewhirst M., Cofer G., Moore D., Burn R. and Olesoa J. Soft-tissue sarcomas: detection of metabolic heterogeneity with P-31 MR spectroscopy. Radiology 176, 837-843 (1990).
14. Zlatkin M. B., Lenkinski R. E., Shinkwin M., Schmidt R. G., Daly J. M., Holland G. A., Frank T. and Kressel H. Y. Combined MR imaging and spectroscopy of bone and soft tissue tumors. J. Comput. Assist. Tomogr. 14, 1-10 (1990).
15. Shinkwin M. A., Lenkinski R. E., Daly J. M., Zlatkin M. B., Frank T. S., Holland G. A. and Kressel H. Y. Integrated magnetic resonance imaging and phosphorus spectroscopy of soft tissue tumors. Cancer 67, 1849-1858 (1991).
16. 31P magnetic resonance spectroscopy. Magn. Reson. Med. 27, 226-237 (1992).
17. Hoekstra H. J., Boeve W. J., Kamman R. L. and Mooyaart E. L. Clinical applicability of human in vivo localized phosphorus-31 magnetic resonance spectroscopy of bone and soft tissue tumors. Ann. Surg. Oncol. 1, 504-511 (1994).
18. Prescott D. M., Charles H. C., Sostman D. H., Dodge R. K., Thrall D. E., Page R. L., Tucker J. A., Harrelson J. M., Leopold K. A., Oleson J. R. and Dewhirst M. W. Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 28, 415-423 (1994).
19. 31P MR spectroscopy Proceedings of the 3rd Annual Meeting of the Society of Magnetic Resonance. p. 1715 (1995).
20. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by by single-dose TNF-α+ Melphalan isolated limb perfusion. NMR Biomed. 8, 215-224 (1995).
21. 31P NMR spectroscopy of human muskoskeletal tumors as a measure of response to chemotherapy. NMR Biomed. 9, 347-358 (1996).
22. 31P NMR spectroscopy of tumors in vivo. Cancer Biochem. Biophys. 8, 157-166 (1986).
23. Griffiths J. R., Bhujwalla Z., Coombes R. C., Maxwell R. J., Midwoood C. J., Morgan R. J., Nias A. H. W., Perry P., Prior M., Prysor-Jones R. A., Rodrigues L. M., Stubbs M. and Tozer G. M. Monitoring cancer therapy by NMR spectroscopy. N. Y. Acad. Sci. 4, 183-199 (1987).
24. Daly P. F. and Cohen J. S. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res. 49, 770-779 (1989).
25. Steen R. G. Response of solid tumors to chemotherapy monitored by in vivo 31P nuclear magnetic resonance spectroscopy: a review. Cancer Res. 49, 4075-4085 (1989).
26. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5, 303-324 (1992).
27. de Certaines J. D., Larsen V. A., Podo F., Carpinelli G., Briot O. and Henriksen O. Studies of human tumors by MRS: a review. NMR Biomed. 6, 345-365 (1993).
28. Brown T. R., Kincaid B. M. and Ugurbil K. NMR chemical shift imaging in three dimensions. Proc. Natl Acad. Sci. USA 79, 3523-3526 (1982).
29. 31P NMR spectroscopy by combining surface coils and slice selective saturation. J. Magn. Reson. 75, 167-173 (1987).
30. Ordidge R. J., Connelly A. and Lohman J. A. B. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson. 66, 283-294 (1986).
31. 13C resonances. Biochim. Biophys. Acta 805, 104-116 (1984).
32. Sostman D., Rockwell S., Smith G. J. W., Gore J. C., Kennedy K. A., Habib A., Fischer J. J., Armitage I. M. and Holcomb W. Magnetic resonance, pathology and physiology of the BA1112 rhabdomyosarcoma in vivo. Invest. Radiat. 23 277-288 (1988).
33. 31P NMR study of the impact of dietary manipulation on tumor metabolism and response to methotrexate. NMR Biomed. 2, 12-18 (1989).
34. 31P-NMR spectroscopy, acid extracts and histology. Br. J. Cancer 60, 701-707 (1989).
35. Negendank W G., Padavic-Shaller K. A., Li C. W., Murphy-Boesch B., Stoyanova R., Krigel R. L., Schilder R. J., Smith M. R. and Brown T. R. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 55, 3286-3294 (1995).
36. Evelhoch J. L., Bissery M. -C., Chabot G. G., Simpson N. E., McCoy C. L., Heilbrun L. K. and Corbett T. H. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48, 4749-4755 (1988).
37. 31P nuclear magnetic resonance spectroscopy. Cancer Res. 48, 4736-4742 (1988).
38. Ballinger J. R., Kang H., Sweeney C. A., Scott J. D., Croker B. P. and Scott K. N. P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Magn. Reson. Imag. 13, 877-883 (1995).
39. 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effect of tumor growth and treatment with 1,3-bis(2-chlorethyl)-1-nitrosurea on tumor energetics and histology. Cancer Res. 48, 676-681 (1988).
40. 31P nuclear magnetic resonance spectroscopy of rat 9L gliosarcoma treated with BCNU: dose response of spectral changes. Magn. Reson. Med. 11, 258-266 (1989).
41. 31P nuclear magnetic resonance spectroscopy is sensitive to tumor hypoxia: perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU. NMR Biomed. 4, 117-124 (1991).
42. Li S. J., Wehrle J. P., Glickson J. D., Kumar N. and Braunschweiger P. G. Tumor bioenergetics and blood flow in RIF-1 murine tumors treated with 5-fluorouracil. Magn. Reson. Med. 22, 47-56 (1991).
43. Sijens P. E., Baldwin N. J. and Ng T. C. Multinuclear MR investigation of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn. Reson. Med. 19, 373-385 (1991).
44. Tozer G. M., Bhujwalla Z. M., Griffiths J. R. and Maxwell R. J. Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following x-radiation. Int. J. Radiat. Oncol. Biol. Phys 16, 155-164, 1989.
45. 31P NMR spectroscopic study of bioenergetic changes in radiation-induced fibrosarcoma-1 after radiation therapy. NMR Biomed. 2 165-171 (1989).
46. Majors A. W., Ng T. C., Karalis I. M., Edinger M. G., Tubbs R. R., Higgins P. D. and Shin K. H. Phosphorus metabolites and the distribution of cell cycle phase of RIF-1 tumors in response to 14 Gy irradiation. Magn. Reson. Med. 16, 425-430 (1990).
47. 31P magnetic resonance spectroscopy. Magn. Reson. Med. 23, 302-310 (1992).
48. 31P magnetic resonance spectroscopy detection of response-predictive adenosine triphosphate decrease in irradiated radiation-induced fibrosarcoma-1 tumors. Invest. Radiol. 32, 39-43 (1997).
49. Bremmer J. C. M., Bradley J. K., Stratford I. J. and Adams G. E. Magnetic resonance spectroscopic studies on 'real-time' changes in RIF-1 tumour metanolismand blood flow during and after photodynamic therapy. Br. J. Cancer 69, 1083-1087 (1994).
50. 2H NMR spectroscopy. NMR Biomed. 2, 64-70 (1992).
51. 31P NMR spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 13, 1851-1855 (1987).
52. 31P NMR spectroscopy of the energy metabolism of malignant tumor in rats during treatment. Radiother. Oncol. 21, 48-52 (1991).
53. Shine N., Palladino M. A., Patton Jr. J. S., Deisseroth A., Kacmar G. S., Matson G. B. and Weiner M. W. Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study. Cancer Res. 49, 2123-7 (1989).
54. Karczmar G. S., Speder A. and Weiner W. M. Acme effects of TNF on tumor metabolism and perfusion. Proceedings of the 8th Annual Meeting of the Society of Magnetic Resonance in Medicine. p. 147 (1989).
55. 31P magnetic resonance spectroscopy. Cancer Res. 52, 71-76, 1992.
56. Kluge M., Elger B., Engel T., Schaefer C., Seega J. and Vaupel P. Acute effect of tumor necrosis factor alpha or lymphotoxin on global blood flow, laser Doppler flux and bioenergetic status of subcutaneous rodent tumors. Cancer Res. 52, 2167-73 (1992).
57. 31P-Nuclear magnetic resonance studies of the effect of recombinant human interleukine 1α on the bioenergetics of RIF-1 tumors. Cancer Res. 48, 6379-6382 (1989).
58. 31P nuclear magnetic resonance analysis of interferon-induced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. Cancer Res. 46, 2849-57 (1986).
59. Podo F., Carpinelli G., di Vito M., Giannini M., Proietti E., Fiers W., Gresser I. and Belardelli F. Nuclear magnetic resonance analysis of tumor necrosis factor-induced alterations of phospholipid metabolites and pH in Friend leukemia cell tumor and fibrosarcoma in mice. Cancer Res. 47, 6481-9 (1987).
60. Lilly M. B., Ng T. C., Evanochko W. T., Katholi C. R., Kumar N. G., Elgavish G. A., Durant J. R., Hiramoto R., Ghanta V. and Glickson J. D. Loss of high-energy phosphate following hyperthermia demonstrated by in vivo P-nuclear magnetic resonance spectroscopy. Cancer Res. 44, 633-638 (1984).
61. Lilly M. B., Katholi C. R. and Ng T. C. Direct relationship between high-energy phosphate content and blood flow in thermally treated murine tumors. J. Natl Cancer Inst. 75, 885-889 (1985).
62. Gadian D. G. Magnetic resonance spectroscopy as a probe of tumour metabolism. Eur. J. Cancer 27, 526-528 (1991).
63. 31P nuclear magnetic resonance spectra in neuroectodermal tumors for the evaluation of the effects of chemotherapy. Cancer Res. 45, 2429-2433 (1985).
64. 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy. Ann. N.Y. Acad. Sci. 508, 200-215 (1987).
65. Sijens P. E., Bovee W. M. M. J., Koole P. and Schipper J. Phosphorus NMR study of the response of a murine mammary tumour to hyperthermia as a function of treatment time and Temperature. Int. J. Hyperthermia 5, 351-357 (1989).
66. Rofstad E. K. NMR spectroscopy in prediction and monitoring of radiation response of tumours in vivo. Int. J. Radiat. Biol. 57, 1-5 (1990).
67. 31P MR spectroscopy. Am. J. Roentgenol. 157, 243-248 (1991).
68. Koutcher J. A., Barnett D., Kornblith A. B., Cowburn D., Brady T. J. and Gerweck L. E. Relationship of in pH and energy status to hypoxic cell fraction an hyperthermia sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 18, 1429-1435 (1990).
69. 31P magnetic resonance spectroscopy. Magn. Reson. Med. 11, 202-208 (1988).
70. 31P MRS observations of tumour energy metabolism. NMR Biomed. 5, 279-89 (1992).
71. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. New Engl. J. Med. 312, 1500-05 (1985).
72. 31P MRS in situ. Magn. Reson. Med. 10, 125-134 (1989).
73. Schilling A., Gewiese B., Berger G., Boese-Landgraf J., Fobbe F., Stiller D., Gallkowski U. and Wolf K. J. Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization. Radiology 182, 887-90 (1992).